Invitae Hereditary Wilms Tumor Panel
Use
The Invitae Hereditary Wilms Tumor Panel analyzes genes associated with predisposition to Wilms tumor. It allows for efficient evaluation of several potential genes based on a single clinical indication. Genetic testing in these genes can confirm a clinical diagnosis, predict disease prognosis, facilitate early detection of symptoms, inform family planning, or promote enrollment in clinical trials. This panel specifically targets heritable germline mutations and is not intended for detecting somatic mutations in tumor tissue.
Special Instructions
Preferred specimen is 3mL whole blood in a purple-top EDTA tube. Alternate specimens such as saliva, buccal swab, and gDNA are accepted. Turnaround time averages 14 days within 10–21 calendar days. The test is New York approved and uses next-generation sequencing (NGS) to cover clinically important regions of each gene, including coding exons and adjacent intronic sequences.
Limitations
This panel may not detect structural rearrangements like inversions, translocations, or gene conversion events, and variants in promoter or non-coding regions are generally excluded unless otherwise specified. Single-exon copy number events may not always be analyzed, and certain details like mosaicism or mapping ambiguity may not be fully resolved. The test is not suitable for somatic mutation detection.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)